Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Neeha Zaidi, MD, is turning the tables on pancreatic cancer. Mutations to a gene called KRAS—a cancer driver common to almost all pancreatic cancers—are now a target for prevention and treatment.

October 30, 2026

Vol.52 No.40

By Valerie Mehl

Podcast

Cancer breakthroughs hit the clinic, cancer policy hits the ballot box

In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, and Jacquelyn Cobb, managing editor, discuss promising developments in cancer research and the growing prominence of cancer as an election issue in Iowa.

October 28, 2026

Conversation with The Cancer Letter

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner

Kevan Shokat, a professor of cellular and molecular pharmacology at UC San Francisco, has won the second annual Stephenson Global Prize for research in pancreatic cancer.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Rasonque (daraxonrasib) consistently provided an overall survival benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma, including those with no identified tumor RAS mutation, according to exploratory subgroup analyses from the phase III RASolute 302 trial.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Camupepimut (ELI-002 7P) demonstrated consistent and favorable treatment-effect trends in patients with and without detectable baseline ctDNA and in patients without prior radiation across multiple pre-specified analyses, according to the results of a randomized phase II study of patients with resected pancreatic ductal adenocarcinoma called AMPLIFY-7P.

October 23, 2026

Vol.52 No.39

Obituary

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

Rachna Shroff, a physician-scientist who spent much of her career researching treatments for pancreatic and biliary cancers, has died at the age of 47. She briefly battled an aggressive cancer of an unknown origin.

October 16, 2026

Vol.52 No.38

By Claire Marie Porter

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS

PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

YOU MAY BE INTERESTED IN

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Cancer breakthroughs hit the clinic, cancer policy hits the ballot box

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on

Renew today!

Subscriber content

Never miss an issue!

Login

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS

PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

YOU MAY BE INTERESTED IN

Lifesaving vaccines: Using KRAS to harness the power of the immune system

Cancer breakthroughs hit the clinic, cancer policy hits the ballot box

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53Shokat was named 2026 Stephenson Global Prize winner

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47Her endowed award will live on

Never miss an issue!

Login

Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner

Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on